In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary

NCI Drug Dictionary

  

pembrolizumab 
A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:anti-PD-1 monoclonal antibody MK-3475
humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide
immunoglobulin G4, anti-(human programmed cell death 1)
US brand name:Keytruda
Code names:MK-3475
SCH 900475